Tarsus Pharmaceuticals
TARS
74 hedge funds and large institutions have $252M invested in Tarsus Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 20 reducing their positions, and 5 closing their positions.
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
35% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 20
7% more funds holding
Funds holding: 69 → 74 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.94% less ownership
Funds ownership: 76.98% → 75.04% (-1.9%)
15% less capital invested
Capital invested by funds: $298M → $252M (-$45.9M)
80% less call options, than puts
Call options by funds: $6K | Put options by funds: $30K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.7M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$1.44M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$524K |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$476K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$458K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.61M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
-$3.46M |
| 3 |
DM
Deerfield Management
New York
|
-$2.46M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$925K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$541K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Janney Montgomery Scott
Philadelphia,
Pennsylvania
| – | -$171K | -11,640 | Closed |
|
77
US Bancorp
Minneapolis,
Minnesota
| – | -$1.16K | -79 | Closed |
|
|
IA
78
IFP Advisors
Tampa,
Florida
| – | -$1K | -30 | Closed |
|
|
S
79
SignatureFD
Atlanta,
Georgia
| – | -$191 | -13 | Closed |
|
TARS Hedge Fund Activity: Q1 2023 in Review
74 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q1 2023, worth a combined $252M — down 15% from $298M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TARS positions and 5 closed out — a net gain of 5 holders — while 27 added to existing stakes and 20 trimmed.
The largest buyer was BlackRock, adding an estimated $1.7M. The largest seller was Cormorant Asset Management, cutting an estimated $4.61M.
- 74 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q1 2023, up from 69 in Q4 2022.
- Funds reported $252M of Tarsus Pharmaceuticals stock for Q1 2023, down 15% quarter-over-quarter.
- 10 funds opened new Tarsus Pharmaceuticals positions in Q1 2023 and 5 closed out, a net change of +5 holders.
- The largest Tarsus Pharmaceuticals buyer in Q1 2023 was BlackRock, an estimated $1.7M added.
- The largest Tarsus Pharmaceuticals seller in Q1 2023 was Cormorant Asset Management, an estimated $4.61M sold.
Based on aggregated 13F filings for Q1 2023.